Outlook on the Worldwide Biosimilars Market to 2025 – Featuring Sandoz, Pfizer, Eli Lilly & Teva Pharmaceutical Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%.

The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.

Based on the treatment site, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to remain the fastest-growing segment of the global market during the biosimilars period. Its benefits, particularly for small players in the market or those that do not have sufficient infrastructure and resources for efficient manufacturing, are driving growth.

Asia Pacific is estimated to register the highest CAGR during the study period.

Geographically, the biosimilars market is dominated by Europe and followed by Asia Pacific in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. The rising aging population, coupled with the massive demand for cost-effective alternative pharmaceuticals, will drive the market in the region over the forecast period.

Market Dynamics

Drivers

• Increasing Demand for Biosimilar Drugs
• Rising Incidence of Chronic Diseases

Restraints

• Complexities in Manufacturing
• Resistance From Biologic Manufacturers

Opportunities

• Emerging Markets
• New Indications and the Patent Expiry of Biologic Products

Challenges

• Stringent Regulatory Requirements

Companies Profiled

• Sandoz
• Pfizer
• Eli Lilly
• Teva Pharmaceutical
• Celltrion
• Biocon
• Amgen
• Samsung Biologics
• Mylan
• Dr. Reddy’s Laboratories
• Stada Arzneimittel Ag
• Coherus Biosciences
• Biocad
• Amega Biotech
• Probiomed
• Boehringer Ingelheim
• Apotex
• Fresenius Kabi
• Gedeon Richter
• Mabxience

For more information about this report visit https://www.researchandmarkets.com/r/py49ij

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900